Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates.
about
Mechanism-based inactivation of CYP450 enzymes: a case study of lapatinibPhase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumorsStatin drug interactions and related adverse reactions.Review of cases of patient risk associated with ginseng abuse and misuseCYP2C8 Genotype Significantly Alters Imatinib Metabolism in Chronic Myeloid Leukaemia Patients.Human hepatocyte assessment of imatinib drug-drug interactions - complexities in clinical translation.Evaluation of utility of pharmacokinetic studies in phase I trials of two oncology drugs.Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions.Role of gemfibrozil as an inhibitor of CYP2C8 and membrane transporters.Suppression of carboxylesterases by imatinib mediated by the down-regulation of pregnane X receptor.Impact of CYP2C8*3 polymorphism on in vitro metabolism of imatinib to N-desmethyl imatinib.Structural identification of imatinib cyanide adducts by mass spectrometry and elucidation of bioactivation pathway.Gemfibrozil impairs imatinib absorption and inhibits the CYP2C8-mediated formation of its main metabolite.Influences of Anlotinib on Cytochrome P450 Enzymes in Rats Using a Cocktail Method.Glucuronidation Converts Clopidogrel to a Strong Time-Dependent Inhibitor of CYP2C8: A Phase II Metabolite as a Perpetrator of Drug–Drug Interactions
P2860
Q28080497-93A69C6A-6477-4E31-A4D7-4344EE883D4AQ33412724-BF4EDAD5-B6C4-45AF-B88E-33D326BF2027Q34292468-3CDB130D-4A3D-4D04-87EB-7068292DAA8EQ35675142-1D4428A5-C013-4A5E-A48C-05E2AF3E2132Q36229161-9743BC04-2011-4104-911D-34DDF72EBAE2Q36243653-339B8D1C-5F74-44D4-96FC-6EBCA426510AQ37320052-59E71140-0397-488C-9D06-C68AB535F7AEQ38684505-0EC1A0FE-4812-4F8B-934E-E5DD94D02751Q38933872-20CADDE9-8DB1-42F8-B1BC-A1291E4ADBA6Q38995804-732EA1CF-034E-4776-9C67-50DE0538CC31Q40751644-5B8929B3-4E18-4ED2-9411-8EC0F5757080Q44430233-A71F43AD-2293-4AF3-99B2-CE7F389D1E4EQ46431899-CC363305-8EAD-4B7A-A523-17D9A523437EQ49449657-7CA9A4F6-D548-4AC9-9EE3-560CA204D46FQ57825105-68CC77A9-053C-4887-98F1-4AC9F5CBECA4
P2860
Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Potent mechanism-based inhibit ...... teract with CYP3A4 substrates.
@en
Potent mechanism-based inhibit ...... teract with CYP3A4 substrates.
@nl
type
label
Potent mechanism-based inhibit ...... teract with CYP3A4 substrates.
@en
Potent mechanism-based inhibit ...... teract with CYP3A4 substrates.
@nl
prefLabel
Potent mechanism-based inhibit ...... teract with CYP3A4 substrates.
@en
Potent mechanism-based inhibit ...... teract with CYP3A4 substrates.
@nl
P2860
P50
P1476
Potent mechanism-based inhibit ...... nteract with CYP3A4 substrates
@en
P2093
P2860
P304
P356
10.1111/J.1476-5381.2011.01732.X
P407
P577
2012-04-01T00:00:00Z